• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Qosina Strengthens Aseptic Capabilities

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Societal CDMO

    IDT Biologika

    Biosynth Carbosynth
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Societal CDMO

    IDT Biologika

    Biosynth Carbosynth
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Current Trends in Analytical Testing

    Improved analytical methods continues to be a current need for nearly every aspect of biopharma manufacturing

    Current Trends in Analytical Testing
    Current Trends in Analytical Testing
    Current Trends in Analytical Testing
    Current Trends in Analytical Testing
    Current Trends in Analytical Testing
    Related CONTENT
    • Precision NanoSystems Announces Plans to Expand Global Headquarters
    • CMO Becoming a Powerhouse With Expansions and New Facilities, Looking to Add Strategic Customers
    • The Real Cost of Bringing Manufacturing Home
    • LGM Pharma Launches Analytical Services for Drug Developers and Manufacturers
    • Frontage to Acquire Quintara Discovery
    Eric S. Langer, BioPlan Associates05.09.17
    The biopharmaceutical manufacturing industry relies on analytical testing to help improve productivity, optimize and monitor processes, characterize biologics and biosimilars, and provide real-time product quality control. All of these are essential in creating a more streamlined process within biomanufacturing, which will result in lower costs, more consistent product quality, and more efficient manufacturing across the board.

    In fact, improved analytical methods continues to be cited as a current need for nearly every aspect of biopharmaceutical manufacturing, according to BioPlan’s “14th Annual Report and Survey of Biopharmaceutical Manufacturing and Production.”1 Figure 1 shows examples of this year’s “General New Product Areas of Interest,” excluding specific up- and downstream technologies, the need for better assays continues to be a critical are of interest, with nearly 18% of respondents seeking better tools. 

    The top concerns included proving comparability between manufacturing batches/lots, host cell protein assays, and biophysical characterizations during process development. The need for improved analytical capabilities exists nearly everywhere in biomanufacturing. Another major arena is in analytical testing for biosimilars. Manufacturers need to show similarity and determine the unique difference between products, often with the same analytical technology used to show comparability between manufacturer’s batches/lots.

    The reason for this interest is that better analytical methods are needed to increase productivity in active agent design, discovery, screening, and optimization. There are still too many products failing, at a great expense, later in development. If a drug candidate is to fail, it is preferable that it occur fast and early.

    Analytical testing commonly outsourced
    Nearly all biopharmaceutical developers use outsourcing for at least some of their services, including analytical testing. Outsourcing allows companies to focus on their core competencies, and allows them to send out more complex activities, or the more repetitive tasks. This provides cost savings by allowing companies to avoid building specialized facilities, hiring staff, etc.

    Looking at 24 different areas of outsourcing today, “analytical testing (other bioassays)” was the top area of outsourcing for biomanufacturers. Approximately 9 in 10 (90.4%) companies outsource at least some of this specialized activity. This trend has held relatively steady over the last six years. As more companies continue to outsource such testing, and as in-house capabilities dwindle, it will become increasingly difficult for biomanufacturers to bring such testing activities back in-house.

    Analytical methods are outsourced partially due to the need for highly specialized staff to run the assays and prepare regulatory filings as well as having the related expensive, high-maintenance equipment up and running. The amount of outsourcing will likely increase in the future, if for no other reason than regulatory agencies will be wanting more characterization and data about products. While it’s clear the industry is already outsourcing at least some of its analytical testing, it’s also clear that this trend will continue into the foreseeable future.

    Given the trends in outsourcing over the past decade, it is not surprising that biomanufacturers indicated the top outsourcing activity projected to be done at significantly higher levels in the next 24 months was “analytical testing: other bioassays” at 29.6%. While this is trending down from a high point of 40.9% in 2015, it still remains the number one response. In addition, analytical testing, the top response for future outsourcing areas, was also near the top (29.1%) in estimated average percentage of activity outsourced by facilities today.

    Trends in process analytical technologies
    Quality management is a critical area for avoiding problems, capacity bottlenecks, and failures in today’s biopharmaceutical manufacturing industry. Regulators are increasingly expecting product applications to include extensive studies showing optimization of product quality, which is largely determined by bioprocessing. One of the crucial quality-related issues of biomanufacturing is process analytical technology ( PAT ).

    PAT is defined by the FDA as “a system for designing, analyzing, and controlling manufacturing through timely measurements (i.e., during processing) of critical quality and performance attributes of raw and in-process materials and processes with the goal of ensuring final product quality.” Adoption of PAT is costly and likely requires dedicated equipment and staff in bioprocessing. Since PAT is voluntary, the added cost and hassle of implementing modifications to already-approved biomanufacturing processes and going through regulatory approval explains why it has not been adopted by the majority of the industry. However, implementing PAT for new processes makes sense as it is an effective method to increase productivity, reduce waste, improve yields, and facilitate other cost-saving measures.

    BioPlan surveyed biomanufacturers on the top hurdles hindering the implementation of Process Analytical Technology. The top concern was “time required to implement”, cited by 80.7% of respondents. That concern was followed closely by “insufficient people in-house to manage implementation” (79.7%) and “cost” (51.7%). An interesting jump seen in this year’s report in analysis of what quality initiatives companies are planning to pursue in the next 12 months. PAT held the top spot again, but the response jumped from 20.3% in 2016 to 29.6% in 2017.

    It is clear from the responses from industry members that PAT adoption will continue to increase. Regulatory agencies will expect more quality programs, particularly as more companies adopt the quality initiatives. In addition, PAT will be accepted as providing more robust bioprocessing, as well as being more cost-effective. The data derived from PAT will become routine and expected, it’s simply a matter of companies realizing they need to allocate the time, resources, and staff toward it or similar programs, particularly for new manufacturing efforts.

    Better analytics needed
    Analytical techniques create improvements in optimization and process control. However, progress in the development and implementation of bioprocessing-related assays and analytical instrumentation has not kept up with industry demands. It’s clear from the survey data that there is a need for improvements in analytical technologies for disposables and single-use systems and increased implementation of process analytical technologies. And while there is a strong trend to outsource analytical technology to their CROs and CMOs (contract research and manufacturing organizations), analytical testing remains a major concern in causing future capacity constraints.

    Biopharmaceutical manufacturers and CMOs indicate that increasing productivity pressures are forcing them to do more with less, in addition to the increased demand by regulatory agencies for better data and documentation on product quality. Regulators want to see that assays and analytical data are used to design bioprocess scale-up through development from the beginning stages. All of these factors move the industry toward better and more analytical technologies.

    The good news is the industry is adopting analytical techniques like PAT, and survey data indicate that companies are looking to adopt new analytical technologies going forward, whether that’s within the biomanufacturers’ companies or through outsourcing. Analytical techniques can create improvements in process control and optimization, and better testing using single-use/disposable bioprocessing equipment can prevent delays in product development. As analytical technologies continue to improve and help move the industry toward better process control, and reduce costs, companies will rely on comparative analytical data to inform development and scale-up of new products. In the end, as companies realize that improved analytical assays will improve bioprocessing productivity and quality, implementation of new analytical technologies will continue moving forward.

    Need for better assays, analytical testing and single-use sensors
    One aspect of biomanufacturing in need of better analytical methods, is in the demand for improved and robust disposable sensors. Single-use equipment or disposables are currently being used in a wide range of applications in biomanufacturing. This demand for sensors is logical, as single-use and disposable equipment can provide faster change-overs and reduce shut-down times. However, one factor that is inhibiting more widespread adoption of single-use equipment involves analytical testing, specifically single-use sensor technology. Most of the sensors and probes used today in stainless steel facilities do not translate well into single-use systems. Unfortunately, there are relatively few robust single-use sensors available, and the ones that are in use remain limited to relatively few analytes. In our report, respondents were asked which single-use sensors they most wanted to be introduced or that needed improvements. Of the 14 analytes identified, not surprisingly, it is the more common ones like pH (70.1%), cell density (61.7%), and dissolved oxygen (57.0%) that topped the list for 2017.  The demand for these sensors has continued consistently over the past five years, and although new technologies are emerging, robust, easy-to-use devices are not coming as quickly as many biomanufacturers would like.

    As biomanufacturers and CMOs integrate disposables into their bioprocesses, the need for reliable and robust disposable sensors will increase. Currently, the majority of single-use disposable systems are in the scale up/clinical production as opposed to commercial applications. Yet, as the industry and regulatory agencies gain more confidence and performance, the greater adoption of single-use systems will necessitate better quality sensors and more analytical testing technologies to drive their use in commercial applications.

    Capacity constraints and analytical testing
    Future capacity constraint in biopharma manufacturing is being impacted by the lack of analytical testing. In fact, after general facility constraints, the lack of effective analytical testing was identified as the second biggest concern in terms of how the industry will handle capacity issues.

    Looking ahead to future capacity issues in biopharmaceuticals, we identified 21 factors that the industry believes may restrict future growth. Defining the factors that manufacturers foresee as capacity constraining issues in the future can guide development today, with the goal of circumventing capacity issues. Overall concerns over capacity constraints have increased in recent years, from about 17% of the industry indicating ‘severe’ or ‘significant’ capacity concerns at commercial scale in 2009, to nearly 30% in 2017. This is partly due to stronger pipelines and fewer developmental failures for many of the larger biopharmaceutical companies. We saw similar results for capacity constraints at clinical scale.

    Causes of future problems, according to our respondents included “analytical testing and drug product release” (36.4%) as the second largest factor. This ranked behind “facility constraints” (60.0%) as likely to cause capacity constraints within the next five years. Although analytical testing was seen as slightly less of a concern compared with the last three years, it is still a significant issue. Separately, when comparing concerns of biopharmaceutical developers versus CMOs, biopharmaceutical developers have significantly higher levels of concern in a few areas, the second being analytical testing and drug product release (37.7% for developers vs. 27.8% for CMOs).

    It is clear that manufacturers and CMOs alike are concerned, specifically about analytical testing, and its impact on future production. Development of better analytical tests, testing methods, and technologies, such as better sensors, will help prevent these capacity constraints that the industry is clearly concerned about. 

    References
    1. 14th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, April 2017, BioPlan Associates, Inc. www.bioplanassociates.com.

    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com;  301-921-5979;  www.bioplanassociates.com
    Related Searches
    • production
    • analytics
    • it
    • Manufacturing
    Suggested For You
    Precision NanoSystems Announces Plans to Expand Global Headquarters Precision NanoSystems Announces Plans to Expand Global Headquarters
    CMO Becoming a Powerhouse With Expansions and New Facilities, Looking to Add Strategic Customers CMO Becoming a Powerhouse With Expansions and New Facilities, Looking to Add Strategic Customers
    The Real Cost of Bringing Manufacturing Home The Real Cost of Bringing Manufacturing Home
    LGM Pharma Launches Analytical Services for Drug Developers and Manufacturers LGM Pharma Launches Analytical Services for Drug Developers and Manufacturers
    Frontage to Acquire Quintara Discovery Frontage to Acquire Quintara Discovery
    Host Cell Impurities, Bioassays, Micro-Flow Imaging Host Cell Impurities, Bioassays, Micro-Flow Imaging
    Genezen Breaks Ground on cGMP Lentiviral Vector Production Facility Genezen Breaks Ground on cGMP Lentiviral Vector Production Facility
    Solvias Acquires Chemic Labs Solvias Acquires Chemic Labs
    Hunt for N-Nitrosamines in Medicinal Products Hunt for N-Nitrosamines in Medicinal Products
    Vibalogics Expands Manufacturing Capacity Vibalogics Expands Manufacturing Capacity
    Cambrex Expands Analytical Services Capabilities Cambrex Expands Analytical Services Capabilities
    Metrics Names Stephanie Emory Associate Director of Pharma Development Metrics Names Stephanie Emory Associate Director of Pharma Development
    Cybin to Leverage Catalent’s Zydis for Psychiatric Drug  Cybin to Leverage Catalent’s Zydis for Psychiatric Drug
    Alcami Names Patrick D. Walsh as Chairman and CEO Alcami Names Patrick D. Walsh as Chairman and CEO
    Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer

    Related Breaking News

    • Breaking News | Drug Development
      Precision NanoSystems Announces Plans to Expand Global Headquarters

      Precision NanoSystems Announces Plans to Expand Global Headquarters

      Will improve capabilities to include the clinical manufacturing of RNA vaccines and therapeutics.
      08.11.21

    • Analytical Services | Biologics, Proteins, Vaccines | Cold Chain Management | GMPs/GCPs | Scale-up/Technology Transfer | Serialization | Solid Dosage/Semi-solids | Vials
      CMO Becoming a Powerhouse With Expansions and New Facilities, Looking to Add Strategic Customers

      CMO Becoming a Powerhouse With Expansions and New Facilities, Looking to Add Strategic Customers

      Aphena is a service provider in the pharmaceutical, OTC, medical device, biologics and personal care industries.

    • The Real Cost of Bringing Manufacturing Home

      The Real Cost of Bringing Manufacturing Home

      Bikash Chatterjee of Pharmatech Associates discusses the reshoring trend, technologies and advances that could help deliver more manufacturing back to the U.S.
      08.04.21


    • Analytical Services | Breaking News | Industry News | Laboratory Testing
      LGM Pharma Launches Analytical Services for Drug Developers and Manufacturers

      LGM Pharma Launches Analytical Services for Drug Developers and Manufacturers

      Analytical testing and stability services covers both drug substance and drug product.
      07.08.21

    • Breaking News | CRO News | Drug Development | Drug Discovery | Industry News
      Frontage to Acquire Quintara Discovery

      Frontage to Acquire Quintara Discovery

      Quintara provides in vitro ADME profiling, bioanalytical services, and dedicated assay development and compound screening.
      07.01.21

    Loading, Please Wait..
    Trending
    • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
    • Pierre Fabre And Lonza Enter Manufacturing Agreement
    • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
    • 17th Annual Contracting & Outsourcing Conference Photos
    • Curia And Replicate Bioscience Enter SrRNA Collaboration
    Breaking News
    • Qosina Strengthens Aseptic Capabilities
    • Pierre Fabre and Lonza Enter Manufacturing Agreement
    • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
    • MasterControl and Elemental Machines Form Biomanufacturing Partnership
    • MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • Newsmakers: Darren Shirley
    • Are You Prepared for the 2023 DSCSA Deadline?
    • Rethinking the Changing Role of the CRO
    • 23rd Annual Salary Survey
    • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    • CEO Spotlight: David Chang
    • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
    • CRO Industry Market Report
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Florida Food Products Acquires Javo
    Roquette Launches Nutralys Rice Protein
    New IADSA Chair Lauds Explorations of Supplementation in Healthcare Policy
    Coatings World

    Latest Breaking News From Coatings World

    The Southern Society for Coatings Technology's 84th Annual Technical Conference A Success
    PPG to Showcase Specialty Automotive, Aerospace Adhesives, Sealants at Adhesives & Bonding Expo
    PPG’s New Paint for a New Start Initiative to Transform 25-plus Schools Worldwide
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most Read Stories This Week—June 25
    Magnetic Insight Announces $17 Million in Series B Funding
    BreatheSuite Adds Brad Fluegel to its Board
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pierre Fabre and Lonza Enter Manufacturing Agreement
    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    Qosina Strengthens Aseptic Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Benefit Exec Joins Madison Reed's Board
    Peroni & Ellis Brooklyn Launch Fragrance Collection Inspired by Italian Spritz Cocktails
    Rhode Is Trending for June, Trendalytics Says
    Happi

    Latest Breaking News From Happi

    Spate’s Nose for the Latest Beauty Trends Says The Skunk Stripe, Collagen Serum and Waterproof Eyeshadow are Top of Mind for Consumers this Summer
    A Suitor Emerges for Revlon, SK Capital’s New Dealmaker & P&G’s Indoor Air Quality Efforts
    Wonder Curl Wins GlossWire's GlossPitch Competition
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
    British Coatings Federation Posts Online History
    Orion Announces Price Increases, Reduced Payment Terms
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PCMC teams with IGT, Fujifilm makes big announcement and more
    Loftware recognized as 'AIDC Company of the Year'
    Schreiner MediPharm highlights sustainability of Needle-Trap technology
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
    Tranzonic Names VP of Supply Chain
    Ontex Climate Action Targets Approved by Science-Based Targets Initiative
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—June 25
    3Spine Inc. Receives IDE Approval for U.S. Pivotal Clinical Trial
    Volume-Based Procurement to Reduce Chinese Orthopedic Market Value
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories
    NREL Names Jennifer Logan to Leadership Team as CFO
    National Grid Renewables Orders 2 GW of First Solar Modules

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login